Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142299 | 0.91 | MAPT (0.55) | MAPTTHRBRXFP1 | |
| SCHEMBL4133197 | 0.89 | MAPT (0.57) | MAPT | |
| SCHEMBL27963386 | 0.88 | MAPT (0.50) | MAPTTHRBRXFP1BACE1 | |
| SCHEMBL4138365 | 0.87 | MAPT (0.62) | MAPTTHRBRXFP1BACE1 | |
| SCHEMBL4138117 | 0.86 | PDE4A (0.58) | MAPTTHRBRXFP1 | |
| SCHEMBL5219984 | 0.85 | MAPT (0.71) | MAPTTHRBRXFP1BACE1 | |
| SCHEMBL4139018 | 0.85 | LMNA (0.48) | MAPT | |
| SCHEMBL4145093 | 0.84 | LMNA (0.47) | MAPT | |
| SCHEMBL4146843 | 0.83 | MAPT (0.57) | MAPT | |
| SCHEMBL4144348 | 0.83 | MAPT (0.65) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309184-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OVARIAN CANCER | UNIVERSITY OF SOUTH ALABAMA (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309184-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OVARIAN CANCER | UNIVERSITY OF SOUTH ALABAMA (US) | 2014-10-16 | — | — | US | disclosed |
| US-8796294-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796294-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796294-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | disclosed |
| EP-2527330-A1 | Inhibitors of the hedgehog pathway | Exelixis, Inc. (US) | 2012-11-28 | — | — | EP | disclosed |
| EP-2527330-A1 | Inhibitors of the hedgehog pathway | Exelixis, Inc. (US) | 2012-11-28 | — | — | EP | disclosed |
| US-20120238570-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS PATENT COMPANY LLC (US) | 2012-09-20 | — | — | US | disclosed |
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | disclosed |
| EP-2134695-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | Exelixis, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2008112913-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112913-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238570-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | SHH, GLI1, SMO | MAPT 3255/4885THRB 2014/4885RXFP1 1050/4885 |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | SHH, GLI1, SMO | MAPT 3269/4885THRB 2062/4885RXFP1 971/4885 |
| US-20140309184-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OVARIAN CANCER | TP53, ANXA5, VHL | MAPT 4180/4885THRB 4706/4885RXFP1 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.